PRNewsWire
12 Aug 2026, 10:50 UTC · 1h ago
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
PRNewsWire
12 Aug 2026, 10:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Protalix reported a significant increase in total revenue to $53.6 million for Q2 2026, up from $25.8 million in the same period of 2025. — A more than 100% year-over-year revenue increase demonstrates strong commercial scaling and execution, which is a primary driver for biotech valuations.
+0.80The company reaffirmed its previously stated 2026 revenue expectations. — Reaffirming guidance provides market stability and suggests that the company's growth trajectory is predictable and on track.
+0.40Protalix maintains a balance sheet with $40.7 million in cash and short-term deposits and no outstanding debt or warrants. — Lack of debt and a clean capital structure reduce the risk of dilutive financing rounds in the near term.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Enrollment continues for the PRX-115 Phase 2 RELEASE clinical trial for uncontrolled gout. — Ongoing trial progression is a necessary but baseline requirement for pipeline value preservation; it is less impactful than realized revenue.
+0.20Which stocks this story touches
The company reported significant revenue growth to $53.6 million and reaffirmed its positive financial outlook for 2026.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Business Wire
24m ago
